Review: The antidepressant agomelatine improves the quality of life of depressed patients: implications for remission

Abstract

One of the ongoing clinical challenges associated with the management of major depressive disorder is the fact that many patients do not achieve complete remission and even fewer patients remain in remission. Residual symptoms and poor treatment adherence are two of the main risk factors for relapse with current therapies. In order to face these challenges, clinicians need new treatment strategies that can provide more sustained, longer-term efficacy and adherence. Agomelatine, an innovative antidepressant, is a melatonergic MT1/MT2 agonist with 5HT2C receptor antagonist activity. Randomized, controlled studies have shown that agomelatine reduces depression symptoms and is well tolerated during short-term and long-term treatment strategies. Low relapse rates (21.7% for agomelatine versus 46.6% for placebo after 6 months of continuation treatment; p < 0.0001) have been reported and are believed to be the result of the cumulative effect of agomelatine at all stages of depression. In particular, specific residual symptoms, such as anxiety and sleep disturbances, which increase the rate of relapse, are significantly improved with agomelatine treatment. Furthermore, quality of life during remission, which can affect adherence rates, is likely to be improved because sexual function and weight are preserved. The combination of these unique properties suggests that treatment with agomelatine will provide more sustained, longer-term remission because antidepressant efficacy is combined with fewer residual symptoms and better tolerability and adherence.

Keywords

Agomelatine anxiety major depressive disorder remission sexual function

Get full access to this article

View all access options for this article.

References

Bull SA

Hu XH

Hunkeler EM

, et al. (2002) Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA288: 1403-1409.

Demyttenaere K.

Adelin A.

Patrick M.

Walthère D.

Katrien de B.

and

Michèle S.

( 2008) Six-month compliance with antidepressant medication in the treatment of major depressive disorder. Int Clin Psychopharmacol23: 36-42.

Fava GA

Grandi S.

Zielezney M.

Canestrari R.

and

Morphy MA

( 1994) Cognitive behavioral treatment of residual symptoms in primary major depressive disorder. Am J Psychiatry151: 1295-1299.

Fava GA

Ruini C.

and

Belaise C.

( 2007) The concept of recovery in major depression. Psychol Med37: 307-317.

Fava M.

Rush AJ

Alpert JE

, et al. (2008) Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry165: 342-351.

Frank E.

Prien RF

Jarrett RB

, et al. (1991) Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry48: 851-855.

Goodwin GM

Emsley R.

Rembry S.

, Rouillon F and the Aglomentine Study Group (2009) Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry70: 1128-1137.

Guilleminault C.

and

Quera Salva MA

( 2006) Impact of the melatonergic antidepressant Valdoxan on sleep-wake rhythms of depressed patients. Eur Neuropsychopharmacol16(suppl 4): 317.

Judd LL

Akiskal HS

Maser JD

, et al. (1998) A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry55: 694-700.

10.

Kasper S.

Hajak G.

Wulff K.

, et al. (2010) Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline. J Clin Psychiatry71(2): 109-120.

11.

Kennedy SH

and

Emsley R.

( 2006) Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol16: 93-100.

12.

Kennedy SH

Rizvi S.

Fulton K.

and

Rasmussen J.

( 2008) A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol28: 329-333.

13.

Kennedy SH

and

Rizvi SJ

(2010) Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs24(6): 479-499.

14.

Kurian BT

, Greer T and Trivedi MH (2009) Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms. Expert Rev Neurother9: 975-984.

15.

Lemoine P.

Guilleminault C.

and

Alvarez E.

( 2007) Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. J Clin Psychiatry68: 1723-1732.

16.

Leproult R.

Van Onderbergen A.

L’hermite-Baleriaux M.

Van Cauter E.

and

Copinschi G.

( 2005) Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin Endocrinol (Oxf)63: 298-304.

17.

Lingam R.

and

Scott J.

( 2002) Treatment non-adherence in affective disorders. Acta Psychiatr Scand105: 164-172.

18.

Loo H.

Hale A.

and

D’haenen H.

( 2002) Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. Int Clin Psychopharmacol17: 239-247.

19.

Mallei M.

Zappettini S.

Musazzi L.

, et al. (2009) Agomelatine reduces glutamate release induced by acute stress, possible synergism between melatonin and 5HT2C properties . Eur Neuropsychopharmacol19(Suppl 3): S441.

20.

Montejo AL

Prieto N.

Terleira A.

, et al. (2010) Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX Scale. J Psychopharmacol24: 111-120.

21.

Montgomery SA

Kennedy SH

Burrows GD

Lejoyeux M.

and

Hindmarch I.

( 2004) Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol19: 271-280.

22.

Morris DW

Rush AJ

Jain S.

, et al. (2007) Diurnal mood variation in outpatients with major depressive disorder: implications for DSMV from an analysis of the Sequenced Treatment Alternatives to Relieve Depression Study data. J Clin Psychiatry68: 1339-1347.

23.

Olie JP

and

Kasper S.

( 2007) Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol10: 661-673.

24.

Paykel ES

( 2008) Partial remission, residual symptoms, and relapse in depression . Dialogues Clin Neurosci10: 431-437.

25.

Peeters F.

Berkhof J.

Delespaul P.

Rottenberg J.

and

Nicolson NA

( 2006) Diurnal mood variation in major depressive disorder. Emotion6: 383-391.

26.

Quera Salva MA

Vanier B.

Laredo J.

, et al. (2007) Major depressive disorder, sleep EEG and agomelatine: an open-label study. Int J Neuropsychopharmacol10: 691-696.

27.

Rush AJ

Kraemer HC

Sackhein HA

, et al. (2006a) Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology31: 1841-1853.

28.

Rush AJ

Trivedi MH

Wisniewski SR

, et al. (2006b) Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry163: 1905-1917.

29.

Soumier A.

Banasr M.

Lortet S.

, et al. (2009) Mechanisms contributing to the phase-dependent regulation of neurogenesis by the novel antidepressant, agomelatine, in the adult rat hippocampus. Neuropsychopharmacology34: 2390-2403.

30.

Stein DJ

Ahokas AA

and

de Bodinat C.

( 2008) Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol28(5): 561-566.

31.

Thase ME

( 2009) Pharmacotherapeutic treatment strategies for antidepressant nonresponse. J Clin Psychiatry70: e42.

32.

Trivedi MH

(2009) Tools and strategies for ongoing assessment of depression: a measurement-based approach to remission. J Clin Psychiatry70(Suppl 6): 26-31.

33.

Trivedi MH

Rush AJ

Wisniewski SR

, et al. (2006) Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry163: 28-40.